United Therapeutics Completes Ralinepag License Agreement

United Therapeutics Corp. has contemplated its license agreement with Arena Pharmaceuticals, Inc., acquiring exclusive, worldwide rights to develop and manufacture the Phase III investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). 

United Therapeutics paid $800 million and Arena is also entitled to potential milestone payments of as much as $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.